← Back to Search

Antioxidant

Mito-MES for Coronavirus

Phase 2
Recruiting
Led By Theodoros Kelesidis, MD, PHD, Msc
Research Sponsored by University of Texas Southwestern Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 14 days after exposure to sars-cov-2
Awards & highlights

Study Summary

"Participants without major health issues will be randomly assigned to take either Mito-MES or a placebo to see if it can help prevent COVID-19 after being in close contact with someone who has the

Who is the study for?
This trial is for adults aged 18-65 who've been exposed to COVID-19 without masks, are asymptomatic, and live with someone diagnosed with the virus. They must test negative for SARS-CoV-2 initially and not have major health issues including kidney or gastrointestinal diseases.Check my eligibility
What is being tested?
The study tests if Mitoquinone (Mito-MES), taken orally, can prevent COVID-19 after high-risk exposure compared to a placebo. Participants will be randomly assigned to either receive Mito-MES or a placebo in this prevention trial.See study design
What are the potential side effects?
Potential side effects of Mitoquinone/Mito-MES may include mild stomach upset or allergic reactions; however, it's being studied as a safe option so severe side effects are not expected.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 14 days after exposure to sars-cov-2
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 14 days after exposure to sars-cov-2 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
SARS-CoV-2 infection
Secondary outcome measures
Duration of symptoms of SARS-CoV-2 infection
Safety of mito-MES
Severity of symptoms of SARS-CoV-2 infection
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Mito-MESExperimental Treatment1 Intervention
MitoQ pills 20 mg orally daily taken during the study and initiated within 3 days post exposure.
Group II: Control groupPlacebo Group1 Intervention
Placebo pills orally daily taken during the study and initiated within 3 days post exposure.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mitoquinone/mitoquinol mesylate
2022
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor
1,057 Previous Clinical Trials
1,054,964 Total Patients Enrolled
Theodoros Kelesidis, MD, PHD, MscPrincipal InvestigatorUT Southwestern Medical Center
~75 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top